Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspen Pharmacare HoldingsAPNHY -1.06%73 EV-to-EBITDA is 128.89 as of Aug. 03, 2026, which is 879% above its 10-year median of 13.16. GuruFocus rates APNHY with a GF Score™ of 73/100 and a GF Value™ of $10.03 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 746 Drug Manufacturers companies, Aspen Pharmacare Holdings ranks worse than 96.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aspen Pharmacare Holdings's enterprise value is $5,568 Mil.
Aspen Pharmacare Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $43 Mil. Therefore, Aspen Pharmacare Holdings's EV-to-EBITDA for today is 128.89.
The historical rank and industry rank for Aspen Pharmacare Holdings's EV-to-EBITDA or its related term are showing as below:
APNHY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.25 Med: 13.16 Max: 140.91
Current: 128.89
During the past 13 years, the highest EV-to-EBITDA of Aspen Pharmacare Holdings was 140.91. The lowest was 7.25. And the median was 13.16.
APNHY's EV-to-EBITDA is ranked worse than 96.38% of 746
companies
in the Drug Manufacturers industry
Industry Median: 12.995
vs APNHY: 128.89
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspen Pharmacare Holdings's PE Ratio (TTM) for today is calculated as:
Aspen Pharmacare Holdings's share price for today is $8.885.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.242.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Aspen Pharmacare Holdings's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspen Pharmacare Holdings EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aspen Pharmacare Holdings's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aspen Pharmacare Holdings's EV-to-EBITDA falls into.
Aspen Pharmacare Holdings's current Enterprise Value is $5,568 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Aspen Pharmacare Holdings's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $43 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspen Pharmacare Holdings (APNHY) has a EV-to-EBITDA of 128.89 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aspen Pharmacare Holdings. This is 879% above median its historical median of 13.16. Over the past decade, Aspen Pharmacare Holdings' EV-to-EBITDA has ranged from 7.25 to 140.91. According to the industry distribution chart, Aspen Pharmacare Holdings ranks #719 out of 746 companies in the Drug Manufacturers industry, placing it in the top 96.4%.
Is Aspen Pharmacare Holdings' EV-to-EBITDA too high?
Aspen Pharmacare Holdings' current EV-to-EBITDA of 128.89 is 879% above median its 10-year median of 13.16. Over the past 10 years, this metric has ranged from a low of 7.25 to a high of 140.91. The Drug Manufacturers industry median EV-to-EBITDA is 13.00. Aspen Pharmacare Holdings' value of 128.89 is 891.8% above this industry median. Based on the distribution chart, Aspen Pharmacare Holdings ranks #719 out of 746 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Aspen Pharmacare Holdings has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aspen Pharmacare Holdings' EV-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aspen Pharmacare Holdings ranks #719 out of 746 companies for EV-to-EBITDA. This places Aspen Pharmacare Holdings in the lower half of its industry. The industry median EV-to-EBITDA is 13.00. Aspen Pharmacare Holdings' value of 128.89 is 891.8% above this benchmark. Historically, Aspen Pharmacare Holdings' own EV-to-EBITDA has ranged from 7.25 to 140.91 over the past decade. While the company's 10-year median is 13.16 vs. the industry median of 13.00, Aspen Pharmacare Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.00, based on 746 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aspen Pharmacare Holdings's current EV-to-EBITDA of 128.89 is 891.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aspen Pharmacare Holdings. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspen Pharmacare Holdings's current EV-to-EBITDA is 128.89, which is 879% above median its own 10-year median of 13.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspen Pharmacare Holdings stock overvalued right now?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings (APNHY) is currently considered Modestly Undervalued. The stock's GF Value™ is $10.03, compared to a current price of $8.89 — trading 11.4% below its estimated fair value. The current EV-to-EBITDA is 128.89, which is 879% above median its 10-year median of 13.16 and 891.8% above the Drug Manufacturers industry median of 13.00. Aspen Pharmacare Holdings' overall GF Score™ is 73/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aspen Pharmacare Holdings (APNHY), the current EV-to-EBITDA is 128.89 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspen Pharmacare Holdings (APNHY) Overvalued in 2026?
Based on GuruFocus' analysis, Aspen Pharmacare Holdings stock appears to be undervalued.
The current stock price of $8.89 is trading 11.4% below its estimated GF Value™ of $10.03.
GuruFocus considers Aspen Pharmacare Holdings to be Modestly Undervalued.
Key valuation signals for APNHY:
EV-to-EBITDA: 128.89 (879% above median its 10-year median of 13.16)
GF Value™: $10.03 vs. price of $8.89 (11.4% below fair value)
Industry Position: 891.8% above the Drug Manufacturers median (#719 of 746)
No single metric tells the full story. See the APNHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspen Pharmacare Holdings Ltd is a multinational pharmaceutical company. The group focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets. The business segments of the group are split between the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals business segments are: Injectables, Over-the-counter, and Prescription. The Manufacturing business segments are: Active Pharmaceutical Ingredients, Finished Dose Form, and Heparin. Its geographic regions are Africa Middle East, Europe CIS, Australasia, Asia, and America.
73GF Score
Get the complete analysis for APNHY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APNHY has been successfully added to your 
